Athersys Inc (ATHX) 1.91 $ATHX Athersys Reports
Post# of 273257
Posted On: 09/03/2016 9:18:42 PM
Athersys Inc (ATHX) 1.91 $ATHX
Athersys Reports Second Quarter 2016 Results
GlobeNewswire - Tue Aug 09, 3:03PM CDT
Athersys, Inc. (Nasdaq:ATHX) today announced its financial results for the three months ended June 30, 2016.
ATHX: 1.91 (-0.03)
Are These Biotech Stocks Prescribed for Investors' Portfolio? - Anacor Pharma, Athersys, Aralez Pharma and Infinity Pharma
PR Newswire - Fri May 20, 7:10AM CDT
The Biotech arena remains under immense pressure, yet many veteran investors believe that the industry is not far from recovering. There are great companies in this space, and today ActiveWallSt.com featured the following four equities: Anacor Pharmaceuticals Inc. (NASDAQ: ANAC), Athersys Inc. (NASDAQ: ATHX), Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ), and Infinity Pharmaceuticals Inc. (NASDAQ: INFI). Sign up for your free trading alerts on these biotech stocks at:
INFI: 1.56 (+0.04), ARLZ: 5.00 (-0.02), ANAC: 99.06 (-0.14), ATHX: 1.91 (-0.03)
Athersys posts 1Q profit
Automated Insights - Thu May 05, 5:57PM CDT
CLEVELAND (AP) _ Athersys Inc. (ATHX) on Thursday reported first-quarter net income of $4.8 million, after reporting a loss in the same period a year earlier.
ATHX: 1.91 (-0.03)
Athersys Reports First Quarter 2016 Results
GlobeNewswire - Thu May 05, 3:07PM CDT
Athersys, Inc. (Nasdaq:ATHX) today announced its financial results for the three months ended March 31, 2016.
ATHX: 1.91 (-0.03)
Athersys to Host First Quarter Financial Results Call
GlobeNewswire - Mon Apr 18, 1:00PM CDT
Athersys, Inc. (Nasdaq:ATHX) will release its first quarter 2016 financial results at approximately 4:00 PM EDT on Thursday, May 5, 2016, and host a conference call shortly thereafter at 4:30 PM EDT to review the results. Gil Van Bokkelen, Chairman and Chief Executive Officer, and William (B.J.) Lehmann, President and Chief Operating Officer, will host the call as follows:
ATHX: 1.91 (-0.03)
Traumatic Brain Injury Pipeline Market 2016 Covering 37 Key Players
PR Newswire - Fri Apr 08, 5:00AM CDT
This 2016 report provides an overview of the Traumatic Brain Injury therapeutic pipeline and helps enhance decision making capabilities to create effective counter strategies & gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
LPTN: 2.35 (-0.02), OMER: 11.10 (+0.34), ATHX: 1.91 (-0.03), KPTI: 10.62 (-0.48), CUR: 0.25 (-0.02)
Why Investors Are So Bullish on This Small Biotech
ACCESSWIRE - Wed Mar 30, 9:30AM CDT
LAS VEGAS, NV / ACCESSWIRE / March 30, 2016 / One major shift we are looking for in healthcare in the coming months is an increased emphasis on bio-electronic medicine, as opposed to pure drug plays. The reason is that the devices currently under development hold the potential to be more effective, with fewer side effects than traditional drug treatments.
ESPR: 10.78 (+0.02), CMRX: 4.62 (unch), GERN: 2.75 (+0.02), CYTX: 2.05 (unch), CLDX: 3.35 (-0.01), SGMO: 4.32 (-0.01), PTCT: 7.91 (+0.12), ATHX: 1.91 (-0.03), MNKD: 0.74 (unch)
Athersys' MultiStem(R) Data to be Presented at International Stroke Conference 2016
GlobeNewswire - Wed Feb 10, 10:00AM CST
Athersys, Inc. (Nasdaq:ATHX) announced today that six presentations featuring Athersys' MultiStem cell therapy treatment for ischemic stroke will be made at the 2016 International Stroke Conference hosted by the American Heart Association, to be held February 17-19, 2016 at the Los Angeles Convention Center, located at 120 South Figueroa Street, Los Angeles, CA. Athersys has recently completed a Phase 2 clinical study of its proprietary cell therapy for the treatment of ischemic stroke and is planning for the next phase of clinical development. A collaboration with Athersys and HEALIOS K.K. was recently announced to develop and commercialize MultiStem for the treatment of stroke in Japan.
ATHX: 1.91 (-0.03)
Athersys to Host Year End 2015 Financial Results Call
GlobeNewswire - Tue Feb 09, 12:00PM CST
Athersys, Inc. (Nasdaq:ATHX) will release its year end 2015 financial results at approximately 4:00 PM EST on Thursday, March 10, 2016, and host a conference call shortly thereafter at 4:30 PM EST to review the results. Gil Van Bokkelen, Chairman and Chief Executive Officer, and William (B.J.) Lehmann, President and Chief Operating Officer, will host the call as follows:
ATHX: 1.91 (-0.03)
Congestive Heart Failure (Heart Failure) - Pipeline Review 2015
M2 - Tue Feb 09, 10:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/lg5hxt/congestive_heart) has announced the addition of the "Congestive Heart Failure (Heart Failure) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Congestive Heart Failure, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Congestive Heart Failure and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Congestive Heart Failure Overview - Therapeutics Development - Pipeline Products for Congestive Heart Failure - Overview - Pipeline Products for Congestive Heart Failure - Comparative Analysis - Congestive Heart Failure - Therapeutics under Development by Companies - Congestive Heart Failure - Therapeutics under Investigation by Universities/Institutes - Congestive Heart Failure - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Congestive Heart Failure - Products under Development by Companies - Congestive Heart Failure - Products under Investigation by Universities/Institutes - Congestive Heart Failure - Companies Involved in Therapeutics Development Companies Mentioned Include: - Allosteros Therapeutics Inc. - Amgen Inc. - AnGes MG, Inc. - Angion Biomedica Corp. - ARCA biopharma, Inc. - Ascelegen Therapeutics, Inc. - Asklepios BioPharmaceutical, Inc. - Athersys, Inc. - Innopharmax Inc. - Jiangsu Hengrui Medicine Co., Ltd. - Juventas Therapeutics, Inc. - La Jolla Pharmaceutical Company - Laboratoires Pierre Fabre SA - Lee's Pharmaceutical Holdings Limited - Les Laboratoires Servier SAS - Lonestar Heart, Inc. - Mast Therapeutics, Inc. - (Others) For more information visit http://www.researchandmarkets.com/research/lg...tive_heart
MSTX: 0.55 (+0.03), AMGN: 169.77 (-0.36), ATHX: 1.91 (-0.03)
Type-1 diabetes (Juvenile Diabetes) Pipeline Review, H2 2015
M2 - Tue Feb 09, 8:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/4jtbk6/type1_diabetes) has announced the addition of the "Type-1 diabetes (Juvenile Diabetes) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Type-1 diabetes (Juvenile Diabetes)and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Type-1 diabetes (Juvenile Diabetes)Overview - Therapeutics Development - Pipeline Products for Type-1 diabetes (Juvenile Diabetes)- Overview - Pipeline Products for Type-1 diabetes (Juvenile Diabetes)- Comparative Analysis - Type-1 diabetes (Juvenile Diabetes)- Therapeutics under Development by Companies - Type-1 diabetes (Juvenile Diabetes)- Therapeutics under Investigation by Universities/Institutes - Type-1 diabetes (Juvenile Diabetes)- Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Type-1 diabetes (Juvenile Diabetes)- Products under Development by Companies - Type-1 diabetes (Juvenile Diabetes)- Products under Investigation by Universities/Institutes - Type-1 diabetes (Juvenile Diabetes)- Companies Involved in Therapeutics Development Companies Mentioned - 35 of the 100 Companies - 4SC AG - Adocia - AiCuris GmbH & Co. KG - Amarantus Bioscience Holdings, Inc. - Ambrx, Inc. - AntriaBio, Inc. - Aphios Corporation - Araim Pharmaceuticals Inc. - Argos Therapeutics, Inc. - Artery Therapeutics, Inc. - Astellas Pharma Inc. - AstraZeneca Plc - Athersys, Inc. - Axxam SpA - Beta-Cell NV - Biocon Limited - Biodel Inc. - Biogenomics Limited - BioLineRx, Ltd. - BioLingus AG - BioTherapeutics Inc. - Boehringer Ingelheim GmbH - Caladrius Biosciences, Inc. - Carlina Technologies SAS - Cellectis S.A. - Compugen Ltd. - Daewoong Pharmaceutical Co., Ltd. - Dance Biopharm Inc. - Diabetology (Products) Ltd - DiaMedica Inc. - Diasome Pharmaceuticals, Inc. - Dompe Farmaceutici S.p.A. - DoNatur GmbH - Effimune SAS - Eli Lilly and Company For more information visit http://www.researchandmarkets.com/research/4j...1_diabetes
AMBX: (), LLY: 76.85 (-0.38), BIOD: 0.42 (unch), CLBS: 4.92 (+0.09), ARGS: 5.23 (+0.28), AZN: 33.31 (+0.71), CGEN: 7.41 (+0.36), ATHX: 1.91 (-0.03)
Schizophrenia Market Pipeline Review, H2 2015
M2 - Fri Feb 05, 10:00AM CST
Research and Markets (http://www.researchandmarkets.com/research/65ggnc/schizophrenia) has announced the addition of the "Schizophrenia - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Schizophrenia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Schizophrenia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Schizophrenia Overview - Therapeutics Development - Pipeline Products for Schizophrenia - Overview - Pipeline Products for Schizophrenia - Comparative Analysis - Schizophrenia - Therapeutics under Development by Companies - Schizophrenia - Therapeutics under Investigation by Universities/Institutes - Schizophrenia - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Schizophrenia - Products under Development by Companies - Schizophrenia - Products under Investigation by Universities/Institutes - Schizophrenia - Companies Involved in Therapeutics Development (Partial List) - Acadia Pharmaceuticals Inc. - Aequus Pharmaceuticals Inc. - Aestus Therapeutics, Inc. - AgeneBio Inc. - Alkermes Plc - Amgen Inc. - Angita B.V. - ANP Technologies, Inc. - Astellas Pharma Inc. - Athersys, Inc. - BCWorld Pharm Co. Ltd. - BioCrea GmbH - Boehringer Ingelheim GmbH - Braeburn Pharmaceuticals, Inc. - Catalyst Biosciences, Inc. - Critical Pharmaceuticals Limited - Curemark, LLC - Delpor, Inc. - Dong Wha Pharma Co., Ltd. - Echo Pharmaceuticals B.V. - Egis Gyogyszergyar Nyrt - Eli Lilly and Company - Evotec AG - F. Hoffmann-La Roche Ltd. - FORUM Pharmaceuticals Inc. - Galenea Corp. - GeNeuro SA - Genovate Biotechnology Co., LTD. - Gilead Sciences, Inc. - Glenmark Pharmaceuticals Ltd. - GP Pharm, S.A. For more information visit http://www.researchandmarkets.com/research/65...izophrenia
ACAD: 31.59 (-0.51), GILD: 76.89 (-0.53), CBIO: 1.25 (+0.05), AMGN: 169.77 (-0.36), LLY: 76.85 (-0.38), ATHX: 1.91 (-0.03), ALKS: 45.12 (+0.38)
Multiple Sclerosis - Pipeline Review, H2 2015 Featuring 174 Companies
M2 - Fri Feb 05, 9:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/97qgw2/multiple) has announced the addition of the "Multiple Sclerosis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Sclerosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Multiple Sclerosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Multiple Sclerosis Overview - Therapeutics Development - Pipeline Products for Multiple Sclerosis - Overview - Pipeline Products for Multiple Sclerosis - Comparative Analysis - Multiple Sclerosis - Therapeutics under Development by Companies - Multiple Sclerosis - Therapeutics under Investigation by Universities/Institutes - Multiple Sclerosis - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Multiple Sclerosis - Products under Development by Companies - Multiple Sclerosis - Products under Investigation by Universities/Institutes - Multiple Sclerosis - Companies Involved in Therapeutics Development - 4D Pharma Plc - 4SC AG - AB Science SA - AbbVie Inc. - Ablynx NV - Acorda Therapeutics, Inc. - Actelion Ltd - Addex Therapeutics Ltd - Aegera Therapeutics Inc. - Aegis Therapeutics, LLC - Affectis Pharmaceuticals AG - AiCuris GmbH & Co. KG - Alkermes Plc - Allozyne, Inc. - Amarna Therapeutics B.V. - Antipodean Pharmaceuticals, Inc. - Antisense Therapeutics Limited - Antitope Limited - Aphios Corporation - Apitope International NV - Arena Pharmaceuticals, Inc. - Argos Therapeutics, Inc. - Array BioPharma Inc. - Arrien Pharmaceuticals, LLC - Artielle ImmunoTherapeutics, Inc. - Athersys, Inc. - Axxam SpA - Baliopharm AG - Bio-Cancer Treatment International Limited - BIOCAD - Biocon Limited - Biogen, Inc. - Biogenomics Limited - Biokine Therapeutics Ltd. - Biomar Microbial Technologies For more information visit http://www.researchandmarkets.com/research/97qgw2/multiple About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
ACOR: 24.27 (-0.07), ALKS: 45.12 (+0.38), ARGS: 5.23 (+0.28), ABBV: 64.12 (+0.09), ATHX: 1.91 (-0.03), ARNA: 1.57 (+0.01), ARRY: 3.50 (-0.02)
Athersys to Present at 18th Annual BIO CEO & Investor Conference
GlobeNewswire - Mon Feb 01, 10:00AM CST
Athersys, Inc. (Nasdaq:ATHX) announced today that it will present at the 18 annual BIO CEO & Investor Conference to be held on February 8-9, 2016 in New York, NY, at The Waldorf Astoria New York.
ATHX: 1.91 (-0.03)
Global Ischemia Therapeutic Development Pipeline Review, H2 2015
M2 - Mon Feb 01, 8:03AM CST
Research and Markets (http://www.researchandmarkets.com/research/4b8tfd/ischemia) has announced the addition of the "Ischemia - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Ischemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ischemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Ischemia Overview - Therapeutics Development - Pipeline Products for Ischemia - Overview - Pipeline Products for Ischemia - Comparative Analysis - Ischemia - Therapeutics under Development by Companies - Ischemia - Therapeutics under Investigation by Universities/Institutes - Ischemia - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Ischemia - Products under Development by Companies - Ischemia - Products under Investigation by Universities/Institutes - Ischemia - Companies Involved in Therapeutics Development - Alize Pharma SAS - Amyndas Pharmaceuticals LLC - AnGes MG, Inc. - Apceth GmbH & Co. KG - Athersys, Inc. - Baxalta Incorporated - Caladrius Biosciences, Inc. - Cellmid Limited - CoDa Therapeutics, Inc. - CohBar, Inc. - Cynata Therapeutics Limited - DNAVEC Corporation - GlaxoSmithKline Plc - Hemostemix Ltd - IntelliCell BioSciences Inc. - Juventas Therapeutics, Inc. - Kasiak Research Private Limited - Lixte Biotechnology Holdings, Inc. - Mesoblast Limited - Miltenyi Biotec GmbH - Mirrx Therapeutics A/S - Multi Gene Vascular Systems Ltd - NoNO, Inc. - Nyken BV - Pathfinder Cell Therapy, Inc. - Pharmicell Co., Ltd. - Pluristem Therapeutics Inc. - Protagenic Therapeutics Inc. - ReNeuron Group Plc - Sihuan Pharmaceutical Holdings Group Ltd. - Stempeutics Research Private Limited - Targazyme, Inc. - Taxus Cardium Pharmaceuticals Group Inc. - TikoMed AB - U.S. Stem Cell, Inc. For more information visit http://www.researchandmarkets.com/research/4b8tfd/ischemia
PSTI: 1.65 (+0.01), GSK: 44.26 (+1.28), CLBS: 4.92 (+0.09), MESO: 4.96 (unch), ATHX: 1.91 (-0.03), BXLT: 46.02 (-0.18)
Athersys and Healios Announce R&D Day
GlobeNewswire - Tue Jan 26, 11:03AM CST
HEALIOS K.K. ("Healios"
(Tokyo Stock Exchange:4593) and Athersys, Inc. ("Athersys" (NASDAQ:ATHX) announced today that the companies will host a joint R&D Day event in New York City on Thursday, February 4, 2016. The presentations will take place at the Harvard Club of New York City, 35 West 44 Street, New York, NY. The event will be held in the Cambridge Room and will begin at 4:30 PM EST and conclude at 6:30 PM EST, with a reception to immediately follow. Advanced registration is required by e-mail at irevent@athersys.com or online at www.athersys.com.
ATHX: 1.91 (-0.03)
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Review, H2 2015
M2 - Wed Jan 20, 5:16AM CST
Research and Markets (http://www.researchandmarkets.com/research/t6wjrw/peripheral) has announced the addition of the "Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Overview - Therapeutics Development - Pipeline Products for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Overview - Pipeline Products for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Comparative Analysis - Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Therapeutics under Development by Companies - Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Therapeutics under Investigation by Universities/Institutes - Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Products under Development by Companies - Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Products under Investigation by Universities/Institutes - Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Companies Involved in Therapeutics Development - Alvogen Korea - AnGes MG, Inc. - AstraZeneca Plc - Athersys, Inc. - Bayer AG - Betagenon AB - Cardiolynx AG - CardioVascular BioTherapeutics, Inc. - Celgene Corporation - Diffusion Pharmaceuticals LLC - DNAVEC Corporation - Hemostemix Ltd - Mesoblast Limited - miRagen Therapeutics, Inc. - Multi Gene Vascular Systems Ltd - Nuo Therapeutics, Inc. - Proteon Therapeutics, Inc. - Recardio GmbH - Resverlogix Corp. - Sagene Pharmaceuticals, Inc. - Stemedica Cell Technologies, Inc. - Symic Biomedical, Inc. - Theravasc, Inc. - ViroMed Co., Ltd. - Yuyu Pharma, Inc. For more information visit http://www.researchandmarkets.com/research/t6wjrw/peripheral
MESO: 4.96 (unch), AZN: 33.31 (+0.71), ATHX: 1.91 (-0.03), PRTO: 9.18 (+0.42), CELGZ: 1.18 (+0.05)
Critical Limb Ischemia - Pipeline Review, H2 2015
M2 - Wed Jan 20, 5:11AM CST
Research and Markets (http://www.researchandmarkets.com/research/htv6p6/critical_limb) has announced the addition of the "Critical Limb Ischemia - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Critical Limb Ischemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Critical Limb Ischemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Critical Limb Ischemia Overview - Therapeutics Development - Pipeline Products for Critical Limb Ischemia - Overview - Pipeline Products for Critical Limb Ischemia - Comparative Analysis - Critical Limb Ischemia - Therapeutics under Development by Companies - Critical Limb Ischemia - Therapeutics under Investigation by Universities/Institutes - Critical Limb Ischemia - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Critical Limb Ischemia - Products under Development by Companies - Critical Limb Ischemia - Products under Investigation by Universities/Institutes - Critical Limb Ischemia - Companies Involved in Therapeutics Development - AnGes MG, Inc. - Apceth GmbH & Co. KG - Athersys, Inc. - Caladrius Biosciences, Inc. - Cynata Therapeutics Limited - DNAVEC Corporation - Hemostemix Ltd - IntelliCell BioSciences Inc. - Juventas Therapeutics, Inc. - Kasiak Research Private Limited - Multi Gene Vascular Systems Ltd - Pharmicell Co., Ltd. - Pluristem Therapeutics Inc. - ReNeuron Group Plc - Stempeutics Research Private Limited - Targazyme, Inc. - TikoMed AB - U.S. Stem Cell, Inc. - Vericel Corporation - ViroMed Co., Ltd. For more information visit http://www.researchandmarkets.com/research/ht...tical_limb
VCEL: 2.25 (+0.02), PSTI: 1.65 (+0.01), ATHX: 1.91 (-0.03), CLBS: 4.92 (+0.09)
Athersys, Inc. (NASDAQ: ATHX) to Receive License Fee of $15 million
ACCESSWIRE - Mon Jan 11, 6:31AM CST
CLEVELAND, OH / ACCESSWIRE / January 11, 2016 / Athersys, Inc. (NASDAQ: ATHX) an international biotechnology company that is focused primarily in the field of regenerative medicine, together with Healios K.K., announced a partnership and license agreement that will focus on the development and commercialization of novel cell therapy treatments, including MultiStem(R) for the treatment of ischemic stroke and potentially other indications, in Japan. The partnership involves MultiStem, a proprietary, patented off-the-shelf stem cell therapy being developed by Athersys, with an initial focus on treating ischemic stroke. Athersys will receive an initial license fee of $15 million, as well as have the opportunity to earn milestone and royalty payments upon the successful accomplishment of specific development and commercialization objectives, including the achievement of certain sales milestones. Development and approval milestones for stroke could total $30 million, in addition to sales milestones that could reach $185 million based on successful commercialization and the achievement of substantial sales of an approved product for treating stroke.
ATHX: 1.91 (-0.03)
Healios and Athersys Enter Into Regenerative Medicine Partnership for Treatment of Stroke Using MultiStem(R) Therapy
GlobeNewswire - Fri Jan 08, 5:00AM CST
Healios K.K. ("Healios" (Tokyo Stock Exchange: 4593) and Athersys, Inc. ("Athersys" (NASDAQ:ATHX) have announced a partnership and license agreement that will focus on the development and commercialization of novel cell therapy treatments, including MultiStem for the treatment of ischemic stroke and potentially other indications, in Japan. The partnership involves MultiStem, a proprietary, patented off-the-shelf stem cell therapy being developed by Athersys, with an initial focus on treating ischemic stroke.
ATHX: 1.91 (-0.03)
Athersys Reports Second Quarter 2016 Results
GlobeNewswire - Tue Aug 09, 3:03PM CDT
Athersys, Inc. (Nasdaq:ATHX) today announced its financial results for the three months ended June 30, 2016.
ATHX: 1.91 (-0.03)
Are These Biotech Stocks Prescribed for Investors' Portfolio? - Anacor Pharma, Athersys, Aralez Pharma and Infinity Pharma
PR Newswire - Fri May 20, 7:10AM CDT
The Biotech arena remains under immense pressure, yet many veteran investors believe that the industry is not far from recovering. There are great companies in this space, and today ActiveWallSt.com featured the following four equities: Anacor Pharmaceuticals Inc. (NASDAQ: ANAC), Athersys Inc. (NASDAQ: ATHX), Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ), and Infinity Pharmaceuticals Inc. (NASDAQ: INFI). Sign up for your free trading alerts on these biotech stocks at:
INFI: 1.56 (+0.04), ARLZ: 5.00 (-0.02), ANAC: 99.06 (-0.14), ATHX: 1.91 (-0.03)
Athersys posts 1Q profit
Automated Insights - Thu May 05, 5:57PM CDT
CLEVELAND (AP) _ Athersys Inc. (ATHX) on Thursday reported first-quarter net income of $4.8 million, after reporting a loss in the same period a year earlier.
ATHX: 1.91 (-0.03)
Athersys Reports First Quarter 2016 Results
GlobeNewswire - Thu May 05, 3:07PM CDT
Athersys, Inc. (Nasdaq:ATHX) today announced its financial results for the three months ended March 31, 2016.
ATHX: 1.91 (-0.03)
Athersys to Host First Quarter Financial Results Call
GlobeNewswire - Mon Apr 18, 1:00PM CDT
Athersys, Inc. (Nasdaq:ATHX) will release its first quarter 2016 financial results at approximately 4:00 PM EDT on Thursday, May 5, 2016, and host a conference call shortly thereafter at 4:30 PM EDT to review the results. Gil Van Bokkelen, Chairman and Chief Executive Officer, and William (B.J.) Lehmann, President and Chief Operating Officer, will host the call as follows:
ATHX: 1.91 (-0.03)
Traumatic Brain Injury Pipeline Market 2016 Covering 37 Key Players
PR Newswire - Fri Apr 08, 5:00AM CDT
This 2016 report provides an overview of the Traumatic Brain Injury therapeutic pipeline and helps enhance decision making capabilities to create effective counter strategies & gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
LPTN: 2.35 (-0.02), OMER: 11.10 (+0.34), ATHX: 1.91 (-0.03), KPTI: 10.62 (-0.48), CUR: 0.25 (-0.02)
Why Investors Are So Bullish on This Small Biotech
ACCESSWIRE - Wed Mar 30, 9:30AM CDT
LAS VEGAS, NV / ACCESSWIRE / March 30, 2016 / One major shift we are looking for in healthcare in the coming months is an increased emphasis on bio-electronic medicine, as opposed to pure drug plays. The reason is that the devices currently under development hold the potential to be more effective, with fewer side effects than traditional drug treatments.
ESPR: 10.78 (+0.02), CMRX: 4.62 (unch), GERN: 2.75 (+0.02), CYTX: 2.05 (unch), CLDX: 3.35 (-0.01), SGMO: 4.32 (-0.01), PTCT: 7.91 (+0.12), ATHX: 1.91 (-0.03), MNKD: 0.74 (unch)
Athersys' MultiStem(R) Data to be Presented at International Stroke Conference 2016
GlobeNewswire - Wed Feb 10, 10:00AM CST
Athersys, Inc. (Nasdaq:ATHX) announced today that six presentations featuring Athersys' MultiStem cell therapy treatment for ischemic stroke will be made at the 2016 International Stroke Conference hosted by the American Heart Association, to be held February 17-19, 2016 at the Los Angeles Convention Center, located at 120 South Figueroa Street, Los Angeles, CA. Athersys has recently completed a Phase 2 clinical study of its proprietary cell therapy for the treatment of ischemic stroke and is planning for the next phase of clinical development. A collaboration with Athersys and HEALIOS K.K. was recently announced to develop and commercialize MultiStem for the treatment of stroke in Japan.
ATHX: 1.91 (-0.03)
Athersys to Host Year End 2015 Financial Results Call
GlobeNewswire - Tue Feb 09, 12:00PM CST
Athersys, Inc. (Nasdaq:ATHX) will release its year end 2015 financial results at approximately 4:00 PM EST on Thursday, March 10, 2016, and host a conference call shortly thereafter at 4:30 PM EST to review the results. Gil Van Bokkelen, Chairman and Chief Executive Officer, and William (B.J.) Lehmann, President and Chief Operating Officer, will host the call as follows:
ATHX: 1.91 (-0.03)
Congestive Heart Failure (Heart Failure) - Pipeline Review 2015
M2 - Tue Feb 09, 10:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/lg5hxt/congestive_heart) has announced the addition of the "Congestive Heart Failure (Heart Failure) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Congestive Heart Failure, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Congestive Heart Failure and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Congestive Heart Failure Overview - Therapeutics Development - Pipeline Products for Congestive Heart Failure - Overview - Pipeline Products for Congestive Heart Failure - Comparative Analysis - Congestive Heart Failure - Therapeutics under Development by Companies - Congestive Heart Failure - Therapeutics under Investigation by Universities/Institutes - Congestive Heart Failure - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Congestive Heart Failure - Products under Development by Companies - Congestive Heart Failure - Products under Investigation by Universities/Institutes - Congestive Heart Failure - Companies Involved in Therapeutics Development Companies Mentioned Include: - Allosteros Therapeutics Inc. - Amgen Inc. - AnGes MG, Inc. - Angion Biomedica Corp. - ARCA biopharma, Inc. - Ascelegen Therapeutics, Inc. - Asklepios BioPharmaceutical, Inc. - Athersys, Inc. - Innopharmax Inc. - Jiangsu Hengrui Medicine Co., Ltd. - Juventas Therapeutics, Inc. - La Jolla Pharmaceutical Company - Laboratoires Pierre Fabre SA - Lee's Pharmaceutical Holdings Limited - Les Laboratoires Servier SAS - Lonestar Heart, Inc. - Mast Therapeutics, Inc. - (Others) For more information visit http://www.researchandmarkets.com/research/lg...tive_heart
MSTX: 0.55 (+0.03), AMGN: 169.77 (-0.36), ATHX: 1.91 (-0.03)
Type-1 diabetes (Juvenile Diabetes) Pipeline Review, H2 2015
M2 - Tue Feb 09, 8:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/4jtbk6/type1_diabetes) has announced the addition of the "Type-1 diabetes (Juvenile Diabetes) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Type-1 diabetes (Juvenile Diabetes)and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Type-1 diabetes (Juvenile Diabetes)Overview - Therapeutics Development - Pipeline Products for Type-1 diabetes (Juvenile Diabetes)- Overview - Pipeline Products for Type-1 diabetes (Juvenile Diabetes)- Comparative Analysis - Type-1 diabetes (Juvenile Diabetes)- Therapeutics under Development by Companies - Type-1 diabetes (Juvenile Diabetes)- Therapeutics under Investigation by Universities/Institutes - Type-1 diabetes (Juvenile Diabetes)- Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Type-1 diabetes (Juvenile Diabetes)- Products under Development by Companies - Type-1 diabetes (Juvenile Diabetes)- Products under Investigation by Universities/Institutes - Type-1 diabetes (Juvenile Diabetes)- Companies Involved in Therapeutics Development Companies Mentioned - 35 of the 100 Companies - 4SC AG - Adocia - AiCuris GmbH & Co. KG - Amarantus Bioscience Holdings, Inc. - Ambrx, Inc. - AntriaBio, Inc. - Aphios Corporation - Araim Pharmaceuticals Inc. - Argos Therapeutics, Inc. - Artery Therapeutics, Inc. - Astellas Pharma Inc. - AstraZeneca Plc - Athersys, Inc. - Axxam SpA - Beta-Cell NV - Biocon Limited - Biodel Inc. - Biogenomics Limited - BioLineRx, Ltd. - BioLingus AG - BioTherapeutics Inc. - Boehringer Ingelheim GmbH - Caladrius Biosciences, Inc. - Carlina Technologies SAS - Cellectis S.A. - Compugen Ltd. - Daewoong Pharmaceutical Co., Ltd. - Dance Biopharm Inc. - Diabetology (Products) Ltd - DiaMedica Inc. - Diasome Pharmaceuticals, Inc. - Dompe Farmaceutici S.p.A. - DoNatur GmbH - Effimune SAS - Eli Lilly and Company For more information visit http://www.researchandmarkets.com/research/4j...1_diabetes
AMBX: (), LLY: 76.85 (-0.38), BIOD: 0.42 (unch), CLBS: 4.92 (+0.09), ARGS: 5.23 (+0.28), AZN: 33.31 (+0.71), CGEN: 7.41 (+0.36), ATHX: 1.91 (-0.03)
Schizophrenia Market Pipeline Review, H2 2015
M2 - Fri Feb 05, 10:00AM CST
Research and Markets (http://www.researchandmarkets.com/research/65ggnc/schizophrenia) has announced the addition of the "Schizophrenia - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Schizophrenia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Schizophrenia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Schizophrenia Overview - Therapeutics Development - Pipeline Products for Schizophrenia - Overview - Pipeline Products for Schizophrenia - Comparative Analysis - Schizophrenia - Therapeutics under Development by Companies - Schizophrenia - Therapeutics under Investigation by Universities/Institutes - Schizophrenia - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Schizophrenia - Products under Development by Companies - Schizophrenia - Products under Investigation by Universities/Institutes - Schizophrenia - Companies Involved in Therapeutics Development (Partial List) - Acadia Pharmaceuticals Inc. - Aequus Pharmaceuticals Inc. - Aestus Therapeutics, Inc. - AgeneBio Inc. - Alkermes Plc - Amgen Inc. - Angita B.V. - ANP Technologies, Inc. - Astellas Pharma Inc. - Athersys, Inc. - BCWorld Pharm Co. Ltd. - BioCrea GmbH - Boehringer Ingelheim GmbH - Braeburn Pharmaceuticals, Inc. - Catalyst Biosciences, Inc. - Critical Pharmaceuticals Limited - Curemark, LLC - Delpor, Inc. - Dong Wha Pharma Co., Ltd. - Echo Pharmaceuticals B.V. - Egis Gyogyszergyar Nyrt - Eli Lilly and Company - Evotec AG - F. Hoffmann-La Roche Ltd. - FORUM Pharmaceuticals Inc. - Galenea Corp. - GeNeuro SA - Genovate Biotechnology Co., LTD. - Gilead Sciences, Inc. - Glenmark Pharmaceuticals Ltd. - GP Pharm, S.A. For more information visit http://www.researchandmarkets.com/research/65...izophrenia
ACAD: 31.59 (-0.51), GILD: 76.89 (-0.53), CBIO: 1.25 (+0.05), AMGN: 169.77 (-0.36), LLY: 76.85 (-0.38), ATHX: 1.91 (-0.03), ALKS: 45.12 (+0.38)
Multiple Sclerosis - Pipeline Review, H2 2015 Featuring 174 Companies
M2 - Fri Feb 05, 9:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/97qgw2/multiple) has announced the addition of the "Multiple Sclerosis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Sclerosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Multiple Sclerosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Multiple Sclerosis Overview - Therapeutics Development - Pipeline Products for Multiple Sclerosis - Overview - Pipeline Products for Multiple Sclerosis - Comparative Analysis - Multiple Sclerosis - Therapeutics under Development by Companies - Multiple Sclerosis - Therapeutics under Investigation by Universities/Institutes - Multiple Sclerosis - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Multiple Sclerosis - Products under Development by Companies - Multiple Sclerosis - Products under Investigation by Universities/Institutes - Multiple Sclerosis - Companies Involved in Therapeutics Development - 4D Pharma Plc - 4SC AG - AB Science SA - AbbVie Inc. - Ablynx NV - Acorda Therapeutics, Inc. - Actelion Ltd - Addex Therapeutics Ltd - Aegera Therapeutics Inc. - Aegis Therapeutics, LLC - Affectis Pharmaceuticals AG - AiCuris GmbH & Co. KG - Alkermes Plc - Allozyne, Inc. - Amarna Therapeutics B.V. - Antipodean Pharmaceuticals, Inc. - Antisense Therapeutics Limited - Antitope Limited - Aphios Corporation - Apitope International NV - Arena Pharmaceuticals, Inc. - Argos Therapeutics, Inc. - Array BioPharma Inc. - Arrien Pharmaceuticals, LLC - Artielle ImmunoTherapeutics, Inc. - Athersys, Inc. - Axxam SpA - Baliopharm AG - Bio-Cancer Treatment International Limited - BIOCAD - Biocon Limited - Biogen, Inc. - Biogenomics Limited - Biokine Therapeutics Ltd. - Biomar Microbial Technologies For more information visit http://www.researchandmarkets.com/research/97qgw2/multiple About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
ACOR: 24.27 (-0.07), ALKS: 45.12 (+0.38), ARGS: 5.23 (+0.28), ABBV: 64.12 (+0.09), ATHX: 1.91 (-0.03), ARNA: 1.57 (+0.01), ARRY: 3.50 (-0.02)
Athersys to Present at 18th Annual BIO CEO & Investor Conference
GlobeNewswire - Mon Feb 01, 10:00AM CST
Athersys, Inc. (Nasdaq:ATHX) announced today that it will present at the 18 annual BIO CEO & Investor Conference to be held on February 8-9, 2016 in New York, NY, at The Waldorf Astoria New York.
ATHX: 1.91 (-0.03)
Global Ischemia Therapeutic Development Pipeline Review, H2 2015
M2 - Mon Feb 01, 8:03AM CST
Research and Markets (http://www.researchandmarkets.com/research/4b8tfd/ischemia) has announced the addition of the "Ischemia - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Ischemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ischemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Ischemia Overview - Therapeutics Development - Pipeline Products for Ischemia - Overview - Pipeline Products for Ischemia - Comparative Analysis - Ischemia - Therapeutics under Development by Companies - Ischemia - Therapeutics under Investigation by Universities/Institutes - Ischemia - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Ischemia - Products under Development by Companies - Ischemia - Products under Investigation by Universities/Institutes - Ischemia - Companies Involved in Therapeutics Development - Alize Pharma SAS - Amyndas Pharmaceuticals LLC - AnGes MG, Inc. - Apceth GmbH & Co. KG - Athersys, Inc. - Baxalta Incorporated - Caladrius Biosciences, Inc. - Cellmid Limited - CoDa Therapeutics, Inc. - CohBar, Inc. - Cynata Therapeutics Limited - DNAVEC Corporation - GlaxoSmithKline Plc - Hemostemix Ltd - IntelliCell BioSciences Inc. - Juventas Therapeutics, Inc. - Kasiak Research Private Limited - Lixte Biotechnology Holdings, Inc. - Mesoblast Limited - Miltenyi Biotec GmbH - Mirrx Therapeutics A/S - Multi Gene Vascular Systems Ltd - NoNO, Inc. - Nyken BV - Pathfinder Cell Therapy, Inc. - Pharmicell Co., Ltd. - Pluristem Therapeutics Inc. - Protagenic Therapeutics Inc. - ReNeuron Group Plc - Sihuan Pharmaceutical Holdings Group Ltd. - Stempeutics Research Private Limited - Targazyme, Inc. - Taxus Cardium Pharmaceuticals Group Inc. - TikoMed AB - U.S. Stem Cell, Inc. For more information visit http://www.researchandmarkets.com/research/4b8tfd/ischemia
PSTI: 1.65 (+0.01), GSK: 44.26 (+1.28), CLBS: 4.92 (+0.09), MESO: 4.96 (unch), ATHX: 1.91 (-0.03), BXLT: 46.02 (-0.18)
Athersys and Healios Announce R&D Day
GlobeNewswire - Tue Jan 26, 11:03AM CST
HEALIOS K.K. ("Healios"
(Tokyo Stock Exchange:4593) and Athersys, Inc. ("Athersys" (NASDAQ:ATHX) announced today that the companies will host a joint R&D Day event in New York City on Thursday, February 4, 2016. The presentations will take place at the Harvard Club of New York City, 35 West 44 Street, New York, NY. The event will be held in the Cambridge Room and will begin at 4:30 PM EST and conclude at 6:30 PM EST, with a reception to immediately follow. Advanced registration is required by e-mail at irevent@athersys.com or online at www.athersys.com. ATHX: 1.91 (-0.03)
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Review, H2 2015
M2 - Wed Jan 20, 5:16AM CST
Research and Markets (http://www.researchandmarkets.com/research/t6wjrw/peripheral) has announced the addition of the "Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Overview - Therapeutics Development - Pipeline Products for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Overview - Pipeline Products for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Comparative Analysis - Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Therapeutics under Development by Companies - Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Therapeutics under Investigation by Universities/Institutes - Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Products under Development by Companies - Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Products under Investigation by Universities/Institutes - Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Companies Involved in Therapeutics Development - Alvogen Korea - AnGes MG, Inc. - AstraZeneca Plc - Athersys, Inc. - Bayer AG - Betagenon AB - Cardiolynx AG - CardioVascular BioTherapeutics, Inc. - Celgene Corporation - Diffusion Pharmaceuticals LLC - DNAVEC Corporation - Hemostemix Ltd - Mesoblast Limited - miRagen Therapeutics, Inc. - Multi Gene Vascular Systems Ltd - Nuo Therapeutics, Inc. - Proteon Therapeutics, Inc. - Recardio GmbH - Resverlogix Corp. - Sagene Pharmaceuticals, Inc. - Stemedica Cell Technologies, Inc. - Symic Biomedical, Inc. - Theravasc, Inc. - ViroMed Co., Ltd. - Yuyu Pharma, Inc. For more information visit http://www.researchandmarkets.com/research/t6wjrw/peripheral
MESO: 4.96 (unch), AZN: 33.31 (+0.71), ATHX: 1.91 (-0.03), PRTO: 9.18 (+0.42), CELGZ: 1.18 (+0.05)
Critical Limb Ischemia - Pipeline Review, H2 2015
M2 - Wed Jan 20, 5:11AM CST
Research and Markets (http://www.researchandmarkets.com/research/htv6p6/critical_limb) has announced the addition of the "Critical Limb Ischemia - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Critical Limb Ischemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Critical Limb Ischemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Critical Limb Ischemia Overview - Therapeutics Development - Pipeline Products for Critical Limb Ischemia - Overview - Pipeline Products for Critical Limb Ischemia - Comparative Analysis - Critical Limb Ischemia - Therapeutics under Development by Companies - Critical Limb Ischemia - Therapeutics under Investigation by Universities/Institutes - Critical Limb Ischemia - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Critical Limb Ischemia - Products under Development by Companies - Critical Limb Ischemia - Products under Investigation by Universities/Institutes - Critical Limb Ischemia - Companies Involved in Therapeutics Development - AnGes MG, Inc. - Apceth GmbH & Co. KG - Athersys, Inc. - Caladrius Biosciences, Inc. - Cynata Therapeutics Limited - DNAVEC Corporation - Hemostemix Ltd - IntelliCell BioSciences Inc. - Juventas Therapeutics, Inc. - Kasiak Research Private Limited - Multi Gene Vascular Systems Ltd - Pharmicell Co., Ltd. - Pluristem Therapeutics Inc. - ReNeuron Group Plc - Stempeutics Research Private Limited - Targazyme, Inc. - TikoMed AB - U.S. Stem Cell, Inc. - Vericel Corporation - ViroMed Co., Ltd. For more information visit http://www.researchandmarkets.com/research/ht...tical_limb
VCEL: 2.25 (+0.02), PSTI: 1.65 (+0.01), ATHX: 1.91 (-0.03), CLBS: 4.92 (+0.09)
Athersys, Inc. (NASDAQ: ATHX) to Receive License Fee of $15 million
ACCESSWIRE - Mon Jan 11, 6:31AM CST
CLEVELAND, OH / ACCESSWIRE / January 11, 2016 / Athersys, Inc. (NASDAQ: ATHX) an international biotechnology company that is focused primarily in the field of regenerative medicine, together with Healios K.K., announced a partnership and license agreement that will focus on the development and commercialization of novel cell therapy treatments, including MultiStem(R) for the treatment of ischemic stroke and potentially other indications, in Japan. The partnership involves MultiStem, a proprietary, patented off-the-shelf stem cell therapy being developed by Athersys, with an initial focus on treating ischemic stroke. Athersys will receive an initial license fee of $15 million, as well as have the opportunity to earn milestone and royalty payments upon the successful accomplishment of specific development and commercialization objectives, including the achievement of certain sales milestones. Development and approval milestones for stroke could total $30 million, in addition to sales milestones that could reach $185 million based on successful commercialization and the achievement of substantial sales of an approved product for treating stroke.
ATHX: 1.91 (-0.03)
Healios and Athersys Enter Into Regenerative Medicine Partnership for Treatment of Stroke Using MultiStem(R) Therapy
GlobeNewswire - Fri Jan 08, 5:00AM CST
Healios K.K. ("Healios"
(Tokyo Stock Exchange: 4593) and Athersys, Inc. ("Athersys" (NASDAQ:ATHX) have announced a partnership and license agreement that will focus on the development and commercialization of novel cell therapy treatments, including MultiStem for the treatment of ischemic stroke and potentially other indications, in Japan. The partnership involves MultiStem, a proprietary, patented off-the-shelf stem cell therapy being developed by Athersys, with an initial focus on treating ischemic stroke. ATHX: 1.91 (-0.03)
(0)
(0)Scroll down for more posts ▼